Status | Study |
Recruiting |
Study Name: Biomarkers for Early Detection of Ovarian Cancer Using Uterine Lavage Condition: Ovarian Cancer Ovarian Carcinoma Fallopian Tube Cancer Date: 2017-05-03 Interventions: Procedure: Uterine lavage Uter |
Recruiting |
Study Name: Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Condition: Acinar Cell Carcinoma Adrenal Cortex Carcinoma Adrenal Gla Date: 2016-07-13 Interventions: Procedure: Biospecimen Collection |
Not yet recruiting |
Study Name: Proof-of-concept Study of Birinapant in Combination With Platinum Based Chemotherapy in Subjects With High Grade Serous Carcinomas Condition: Advanced Newly Diagnosed or Recurrent High Grade Serous Carcinomas (HGSC) Date: 2016-04-22 Interventions: Drug: Birinapant Birinapant - |
Recruiting |
Study Name: A Phase II Evaluation of Afatinibin Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma Condition: HER2/Neu+ Uterine Serous Carcinoma Date: 2015-07-02 Interventions: Drug: Afatinib Afatinib, 40 mg orally once daily on a 21 day cycle for the first 12 weeks, then every 28 |
Active, not recruiting |
Study Name: Non Ivasive Prenatal Diagnosis (NIPD) of Cystic Fibrosis Condition: Noninvasive Mucinous Cystadenocarcinoma of Ovary Date: 2014-04-22 Interventions: Other: A sampling of blood A sampling of blood de 14 ml |
Recruiting |
Study Name: Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Condition: Ovarian Brenner Tumor Ovarian Carcinosarcoma Ovarian Clear Date: 2014-03-28 Interventions: Drug: Gemcitabine Hydrochloride |
Terminated |
Study Name: Endoscopic Ultrasound (EUS) Guided Ethanol With Paclitaxel Ablation for Pancreatic Mucinous Cystic Neoplasm Condition: Mucinous Cystic Tumor With Moderate Dysplasia Mucinous Cystadenoma of Pancreas Date: 2012-02-01 Interventions: Drug: Ethanol and Paclitaxel Injection Endoscopic ultrasound will be used to locate and assess the pancr |
Completed |
Study Name: TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer Condition: Malignant Ovarian Mixed Epithelial Tumor Ovarian Brenner Tumor Date: 2011-02-10 Interventions: Drug: TLR8 Agonist VTX-2337 Gi |
Suspended |
Study Name: Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer Condition: Nausea and Vomiting Ovarian Brenner Tumor Ovarian Clear Ce Date: 2011-01-11 Interventions: Procedure: Adjuvant Therapy An |
Completed |
Study Name: Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer Condition: Ovarian Clear Cell Cystadenocarcinoma Stage III Ovarian Cancer Date: 2010-09-04 Interventions: Drug: Carboplatin Given IV |